TWI811428B - 雙環雜芳香環衍生物 - Google Patents

雙環雜芳香環衍生物 Download PDF

Info

Publication number
TWI811428B
TWI811428B TW108129669A TW108129669A TWI811428B TW I811428 B TWI811428 B TW I811428B TW 108129669 A TW108129669 A TW 108129669A TW 108129669 A TW108129669 A TW 108129669A TW I811428 B TWI811428 B TW I811428B
Authority
TW
Taiwan
Prior art keywords
group
alkyl
hydroxyl
compound
alkyl group
Prior art date
Application number
TW108129669A
Other languages
English (en)
Chinese (zh)
Other versions
TW202021971A (zh
Inventor
杵渕政彦
近藤丈和
落合貢司
西谷洋輔
Original Assignee
日商杏林製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商杏林製藥股份有限公司 filed Critical 日商杏林製藥股份有限公司
Publication of TW202021971A publication Critical patent/TW202021971A/zh
Application granted granted Critical
Publication of TWI811428B publication Critical patent/TWI811428B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW108129669A 2018-08-21 2019-08-20 雙環雜芳香環衍生物 TWI811428B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-154411 2018-08-21
JP2018154411 2018-08-21

Publications (2)

Publication Number Publication Date
TW202021971A TW202021971A (zh) 2020-06-16
TWI811428B true TWI811428B (zh) 2023-08-11

Family

ID=69593150

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108129669A TWI811428B (zh) 2018-08-21 2019-08-20 雙環雜芳香環衍生物

Country Status (19)

Country Link
US (1) US11952387B2 (https=)
EP (1) EP3842439A4 (https=)
JP (1) JP7309725B2 (https=)
KR (1) KR20210046649A (https=)
CN (2) CN112752761B (https=)
AU (1) AU2019324089B2 (https=)
BR (1) BR112021002515A2 (https=)
CA (1) CA3104054A1 (https=)
CL (1) CL2020003116A1 (https=)
CO (1) CO2021000512A2 (https=)
IL (1) IL278885A (https=)
MX (1) MX2020013039A (https=)
MY (1) MY200452A (https=)
PH (1) PH12020551991A1 (https=)
SA (1) SA520420914B1 (https=)
SG (1) SG11202012616RA (https=)
TW (1) TWI811428B (https=)
WO (1) WO2020040104A1 (https=)
ZA (1) ZA202101146B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024231436A1 (en) * 2023-05-11 2024-11-14 Arxada Ag Hydrogenation of cyclic ketones

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2127545A1 (fr) * 1992-02-25 1993-09-02 Anne Bousseau Nouvelle application therapeutique de derives de pyridylpyrrolothiazole carboxamide
CN1849323A (zh) * 2003-09-09 2006-10-18 P·安杰莱蒂分子生物学研究所 作为抗病毒药的噻吩并吡咯
WO2009040552A2 (en) * 2007-09-27 2009-04-02 Centro Nacional De Investigaciones Oncológicas (Cnio) Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof
TW201014842A (en) * 2008-09-03 2010-04-16 Boehringer Ingelheim Int Use of quinazoline derivatives for the treatment of viral diseases
CN102388055A (zh) * 2009-04-02 2012-03-21 西班牙国家癌症研究中心 咪唑并[2,1-b][1,3,4]噻二唑衍生物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT65486B (en) 1975-08-28 1978-03-24 Lilly Co Eli Process for the preparation of carbonil-substituted 1-sulfonylbenzimidazoles
JPH0649066B2 (ja) * 1985-02-14 1994-06-29 積水化学工業株式会社 医療用粘着シ−トもしくはテ−プ
US5349068A (en) 1992-04-15 1994-09-20 Sterling Winthrop Inc. 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
JPH07188017A (ja) * 1993-09-30 1995-07-25 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体を含有する抗ウイルス剤
US5453433A (en) 1994-05-13 1995-09-26 Sterling Winthrop Inc. Thiadiazoles and antipicornaviral compositions
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
JPH11106340A (ja) 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
US6258831B1 (en) * 1999-03-31 2001-07-10 The Procter & Gamble Company Viral treatment
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US7229480B2 (en) 2004-02-13 2007-06-12 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
EP2016075A1 (en) 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
EP2307425B1 (en) * 2008-07-29 2014-03-26 Merck Patent GmbH Imidazothiadiazoles derivatives
ES2665277T3 (es) 2009-03-13 2018-04-25 Katholieke Universiteit Leuven K.U. Leuven R&D Análogos de purina y su uso como agentes inmunosupresores
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
US9309236B2 (en) 2011-10-05 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University PI-kinase inhibitors with broad spectrum anti-infective activity
EP3409666A3 (en) 2012-06-07 2019-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
WO2014078813A1 (en) 2012-11-19 2014-05-22 Irm Llc Compounds and compositions for the treatment of parasitic diseases
SG11201504291SA (en) 2012-12-20 2015-07-30 Ucb Biopharma Sprl Therapeutically active pyrazolo-pyrimidine derivatives
EP3004060B1 (en) 2013-05-30 2019-11-27 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
RU2689788C2 (ru) 2014-01-22 2019-05-29 Куровир Аб ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ СОЕДИНЕНИЙ
JP6678599B2 (ja) 2014-06-13 2020-04-08 ユニバーシティー オブ ロチェスター 小分子排出ポンプ阻害剤
GB201410816D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201410815D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201410817D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
CN107949563B (zh) 2015-06-24 2020-06-05 库洛维公司 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物
EP3118198A1 (en) 2015-07-13 2017-01-18 MMV Medicines for Malaria Venture Anti-malarial agents
WO2017044889A1 (en) 2015-09-10 2017-03-16 The Regents Of The University Of California Lrh-1 modulators
WO2017053192A1 (en) 2015-09-21 2017-03-30 The Board Of Regents Of The University Of Texas System Biomarkers of response to hif-2-alpha inhibition in cancer and methods for the use thereof
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201517264D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
WO2017147526A1 (en) 2016-02-26 2017-08-31 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US20190358196A1 (en) 2016-07-27 2019-11-28 Henry C. Lowe Pi 4-kinase inhibitor as a therapeutic for viral hepatitis, cancer, malaria. autoimmune disorders and inflammation, and a radiosensitizer and immunosuppressant

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2127545A1 (fr) * 1992-02-25 1993-09-02 Anne Bousseau Nouvelle application therapeutique de derives de pyridylpyrrolothiazole carboxamide
CN1849323A (zh) * 2003-09-09 2006-10-18 P·安杰莱蒂分子生物学研究所 作为抗病毒药的噻吩并吡咯
WO2009040552A2 (en) * 2007-09-27 2009-04-02 Centro Nacional De Investigaciones Oncológicas (Cnio) Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof
TW201014842A (en) * 2008-09-03 2010-04-16 Boehringer Ingelheim Int Use of quinazoline derivatives for the treatment of viral diseases
CN102388055A (zh) * 2009-04-02 2012-03-21 西班牙国家癌症研究中心 咪唑并[2,1-b][1,3,4]噻二唑衍生物

Also Published As

Publication number Publication date
WO2020040104A1 (ja) 2020-02-27
JPWO2020040104A1 (ja) 2021-08-12
EP3842439A4 (en) 2022-04-27
CN118084937A (zh) 2024-05-28
ZA202101146B (en) 2022-07-27
AU2019324089B2 (en) 2024-06-13
BR112021002515A2 (pt) 2021-07-27
KR20210046649A (ko) 2021-04-28
US20220332730A1 (en) 2022-10-20
AU2019324089A1 (en) 2020-12-10
CL2020003116A1 (es) 2021-04-16
SG11202012616RA (en) 2021-02-25
US11952387B2 (en) 2024-04-09
CN112752761A (zh) 2021-05-04
CO2021000512A2 (es) 2021-01-29
JP7309725B2 (ja) 2023-07-18
MY200452A (en) 2023-12-27
CN112752761B (zh) 2024-03-29
IL278885A (en) 2021-01-31
CA3104054A1 (en) 2020-02-27
MX2020013039A (es) 2021-02-26
SA520420914B1 (ar) 2023-12-25
TW202021971A (zh) 2020-06-16
PH12020551991A1 (en) 2021-08-02
EP3842439A1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
TWI843142B (zh) 用作shp2抑制劑的化合物及其應用
JP6506880B2 (ja) Ｂ型肝炎ウィルス感染症の治療および予防のための新規な四環式４−オキソ−ピリジン−３−カルボン酸誘導体
TWI312779B (https=)
CN109843872B (zh) 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
JP6358639B2 (ja) ６員複素環誘導体およびそれらを含有する医薬組成物
TW202029960A (zh) 新穎吲唑化合物或其鹽
CN110577526A (zh) 溴域结构蛋白抑制剂的盐及其制备方法和应用
MX2013001202A (es) Compuestos de piridina de anillo fusionado.
TWI811428B (zh) 雙環雜芳香環衍生物
WO2010090304A1 (ja) アシルグアニジン誘導体
WO2022037648A1 (zh) 吡唑硼酸类化合物、包含其的药物组合物及它们的用途
CN112585124A (zh) 用于合成sglt抑制剂的中间体的制备方法
TW201930268A (zh) 吲哚胺2,3-雙加氧酶抑制劑以及它們在醫學上的應用
WO2009074020A9 (zh) α-氨基-N-取代酰胺化合物、包含该化合物的药物组合物及其用途
CN109384727B (zh) 酞嗪酮类化合物、其制备方法、药物组合物及用途
HK40051492A (en) Bicyclic heteroaromatic ring derivative
RU2798838C2 (ru) Бициклическое гетероароматическое кольцевое производное
JP2012520258A (ja) 三環式ヘテロ環式誘導体
JP2024538727A (ja) マボリキサフォルの合成およびその中間体
CN107445958A (zh) 一种abt‑199中间体的制备方法
CN119285569A (zh) 一类五元氮杂环类衍生物及其制备方法和应用
TW202547465A (zh) ３－（２－氯嘧啶－４－基）－１－環丙基－１ｈ－吲哚及其衍生物的製備方法
WO2010074764A1 (en) Synthesis of oligomeric neolignans and their use
JP2018070604A (ja) ６員複素環誘導体を含有する医薬組成物
CN108586446A (zh) 三嗪类化合物及其制备方法和抗肿瘤应用